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TAU PROTEIN
Group of heterogeneous neurodegenerative diseases characterized by the deposition of filamentous accumulations of hyperphosphorylated Tau.
TAUOPATHIES
Rodents are the most used animal models to study Tauopathies,
but these neurodegenerative diseases do not occur
spontaneously in laboratory mice and rats. Nevertheless, it
appears to affect other mammalian species.
• To study the role of Tau protein and human Tauopathies.
• To review the use of dogs and cats as spontaneous animal




Tau inclusions are the 
predominant pathology
SECONDARY TAUOPATHY
Tau inclusions with another 
neuropathological hallmark
It is a microtubule-associated protein (MAP) in neurons and glial cells. 
Binds tubulin and promotes and stabilizes microtubules:
• Maintains axonal transport and neuronal integrity.










Human 80 - 6 (3R + 4R) Yes Yes
Mouse 2 88% 3 (4R) No No
Dog 15 92% 4 (3R + 4R) Few Yes
Cat 15 93% 5 (3R + 4R) Substantial Yes
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✓ Elderly dogs and cats develop tau inclusions with cognitive deficits, so both could be valuable animal models of Tauopathies.
However, there are limitations…
• Not replication of all aspects of human Tauopathies → Intermediate model between humans and other models.
• Late onset of disease in comparison with rodent models→ Companion animals as a preclinical model.
• Disparity between antibodies and protocols → Technical protocols need to be refined.
✓Additional research is needed to clarify the differences between human and animal Tauopathies.
CONCLUSIONS
COGNITIVE DYSFUNCTION SYNDROME
Neurodegenerative process related to the ageing of dogs and cats.
✓ Background for studying the factors that influence ageing (genetic,
comorbidities, environment, nutrition…) and increasing life expectancy.
✓ Behavioural changes (disorientation, house soiling…).
✓ Neuropathological changes (cortical atrophy, βA plaques…).
• Hyperphosphorylated Tau in neurons and glial cells of hippocampus,
entorhinal cortex and cerebral cortex.
Spontaneous model for human Tauopathies
&
Development of new veterinary diagnostic procedures and treatments
Figure 7. Immunohistochemistry showing Tau
neurofibrillary inclusions in an aged demented dog.
Modified from Smolek et al. (2016).
Alzheimer’s disease




Table 1. Comparison of Tau pathology. The formation of NFTs differs between species, what 
could be associated with the life span of the animal and the sequence and isoforms of Tau.
✓ NFTs are not a common characteristic of the
aged dog brain.
Figure 8. Immunohistochemistry showing NFTs and
Tau inclusions in aged cats brains. Modified from
Chambers et al. (2015) and Poncelet et al. (2019).
✓ The formation of NFTs follows the same staging
and spatial distribution as human Tauopathies.
Hyperphosphorylated 




labelling NFTs, which are often
flame-shaped. Modified from Götz et
al. (2019).
Figure 5. Immunohistochemistry
showing plaques of βA (arrows) and
NFTs (arrowheads). Modified from






Götz et al. (2019).
Figure 3. Tau protein in
primary tauopathies. Modified
from Götz et al. (2019).
Figure 6. Tau protein in
Alzheimer’s disease. Modified






Changes tau shape 
and regulates 
negatively its activity
mRNA splicing 6 isoforms in the 
human brain
Figure 2. Diagram of Tau pathology. Modified from Barron et al. (2017).
